Volkswagen Group Diesel Efficiency Foundation (VGDES) and the Consumentenbond Announce that Court Once Again Rules Against Volkswagen in Dutch Dieselgate Proceedings
On Friday October 6, 2023, the Sub-District Court of Oost-Brabant (‘s-Hertogenbosch) ruled that Volkswagen must compensate yet another Dutch Dieselgate consumer who purchased a VW vehicle containing illegal defeat device software. The Court ruled that Volkswagen must pay €4440 - the equivalent of 10% of the vehicle’s purchase price.
This is the latest of four lawsuits brought by the Volkswagen Group Diesel Efficiency Foundation (VGDES) (a Dutch organization representing consumer rights) and Consumentenbond (the Dutch consumer rights organization) on behalf of consumers defrauded by VW. Earlier this year, in March, April and July 2023, other Dutch courts all ruled against Volkswagen finding that it must pay damages to Dutch consumers who similarly purchased vehicles equipped with illegal software. In those prior rulings, the courts awarded €3,000 for an impacted new VW diesel vehicle and €1,500 for a used one. In this latest opinion, the judge increased the penalty finding that those amounts were too low, and determining that the appropriate sanction was a percentage of the vehicle’s purchase price.
A Fourth Defeat for Volkswagen
“This is the fourth time in a row that the Court has ruled against Volkswagen,” said Dick Bouma, chairman of VGDES. “The judge swept aside all VW’s technical legal defenses, and simply found that the car maker deceived consumers. Courts here and all over the world have determined that the company has deliberately misled consumers, including by promoting these diesel cars as environmentally friendly. It is time for Volkswagen to compensate harmed consumers.”
Volkswagen Should Resolve the Claims of the Hundreds of Thousands Dutch Consumers
Sandra Molenaar, Consumentenbond CEO, is pleased with the ruling and looks ahead: “So far we have won all four lawsuits against VW concerning its illegal use of defeat device software in diesel cars. Following this even stronger decision, we again invite Volkswagen to engage in settlement talks. Hopefully, the company is now prepared to compensate all affected Dutch consumers. If not, there are thousands of individual cases we can file against the Company. And, if necessary, we will take each and every case to court to hold Volkswagen accountable and to force the Company to compensate all impacted consumers.”
Links
- March: https://www.consumentenbond.nl/nieuws/2023/doorbraak-in-volkswagen-dieselschandaal-rechter-wijst-compensatie-toe
- April: https://www.consumentenbond.nl/nieuws/2023/weer-succes-in-rechtszaak-om-volkswagen-sjoemeldiesel
- July: https://www.consumentenbond.nl/nieuws/2023/volkswagen-moet-eigenaar-tweedehands-sjoemeldiesel-1500euro-betalen
- October: https://www.consumentenbond.nl/nieuws/2023/volkswagen-opnieuw-veroordeeld-in-dieselgate-procedure
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231011132017/en/
Contact information
Source/Contact
Gerard Spierenburg
Consumentenbond
gspierenburg@consumentenbond.nl
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 01:49:00 EET | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive Officer, Lattice Semiconductor. The annual GSA Awards celebrate the accomplishments of the semiconductor indu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom